Clinical Trial Update: Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject. [Phase 1]

View source ↗

Summary

Phase 1 study update assessing PK/PD characteristics, safety, and tolerability of a new CKD-519 formulation in healthy male subjects; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• CKD-519 New Formulation (CKD-519)

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Dyslipidemia | Phase 1 | Status: COMPLETED